GlassScriptPhysician profile
Jane L Neumann
NPI 1548237282
$1,345.18
in general payments reported to CMS, 2019-2025
18 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $143 · 2021: $52.67 · 2022: $241 · 2023: $33.88 · 2024: $197 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.33 | 2019-2025 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $208.61 | 2019-2025 | Nucala |
| Mylan Specialty L.P. | $126.45 | 2019-2020 | |
| Organogenesis INC. | $125.00 | 2022 | |
| Kerecis Limited | $107.75 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.22 | 2019-2020 | |
| Genzyme Corporation | $56.89 | 2019-2020 | |
| Amgen INC. | $52.37 | 2023-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $41.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.95 | 2024-2025 | Glassia |
| Shire North American Group INC | $30.65 | 2019 | |
| Csl Behring | $24.46 | 2020 | |
| Genentech USA, INC. | $21.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.57 | 2021 | |
| Verona Pharma, INC. | $20.06 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $19.25 | 2019 | |
| Insmed, INC. | $18.93 | 2025 | Brinsupri, Arikayce |
| Teva Pharmaceuticals USA, INC. | $16.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.